Q3 2021 Sumitomo Dainippon Pharma Co Ltd Earnings Call Transcript
My name is Hiroshi Nomura. I am the President and CEO of Sumitomo Dainippon Pharma. Thank you for joining the conference call for the third quarter of fiscal year 2020.
As you have probably noticed in the presentation material as well as supplementary financial data, we did not revise the financial forecast. This is because there are some variables that make it difficult to make forecasts. More specifically, that's napabucasin colorectal cancer study has in Phase III. The top line results were supposed to come out in July last year, as you recall. However, due to the COVID-19 pandemic, data cleaning process took longer. This month, in January, we are pleased to have completed data cleaning, and we are diligently working on analysis.
In February, long-awaited results for napabucasin study will be revealed. Once the results are available, we will announce the full year financial outlook. Because the study results will be available soon after this conference call, we would like to wait for the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
